Lintuzumab (HuM-195) is a non-coupled humanized mouse monoclonal antibody directed against the cell-surface myelomonocyte differentiation antigen, CD33, with anti-leukemic activity that reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells.Lintuzumab has antitumor activity and induces cell death directly via CDC or ADCC. Lintuzumab has anti-tumor activity and induces cell death directly via CDC or ADCC.

Characteristic MSH-Tetrapeptide

反式-2-十一烯酸 ((E)-2-十一烯酸) 是一种 α,β-不饱和羧酸，其特征为酸二聚体。